Clinical Trial Update: A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating JSKN003 against Trastuzumab, in combination with Pertuzumab and Docetaxel, as first-line therapy for HER2-positive recurrent…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Metastatic Breast Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• JSKN003
• Pertuzumab (pertuzumab)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Shanghai JMT-Bio Inc. | Conditions: HER2-positive Recurrent or Metastatic Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING